An observational study in Glioblastoma, sponsored by Erasmus Medical Center. Not yet recruiting at 6 sites in Netherlands. Open to participants aged 70 Years to 95 Years. Per ClinicalTrials.gov, last updated 2022-12-07.
Sponsored by Erasmus Medical Center · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 92 studies in Glioblastoma with a site in Netherlands — 24 open to participants now, 33 under way, 5 of them phase 3. Glioblastoma · Netherlands.
Among the 92 studies in Glioblastoma with a site in Netherlands, this one is the 8th largest by planned enrollment of the 15 observational ones that give a count, is one of 9 that started in 2023, is one of 15 observational ones, reaches primary completion later than 10 of the 32 other live ones, and was the 67th registered.
2,137 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.
Browse Glioblastoma studies →24 of the 92 studies in Glioblastoma with a site in Netherlands are open now. Recruiting first, the newest first:
Erasmus Medical Center · Sites in Netherlands
Ages 18+
Telix Pharmaceuticals (Innovations) Pty Limited · Sites in Netherlands, Australia, Austria and 1 more country
Ages 18+
Nationwide Children's Hospital · Sites in Netherlands, United States, Australia and 3 more countries
Ages 1–21 · Healthy volunteers
Bayer · Sites in Netherlands, United States, Australia and 10 more countries
Ages 18+
Rigel Pharmaceuticals · Sites in Netherlands, United States, Australia and 4 more countries
Ages 12–39
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 339 Glioblastoma studies recruiting now, 235 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.
This study: 70 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
92 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 28 · Phase 2 24 · Phase 3 18 · Phase 4 1
First in 1999; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 325 is above the median of 60 across 208 observational studies indexed under Glioblastoma.
Median enrollment 76 across the 77 interventional studies, 325 across the 15 observational. Of the 53 that completed or were terminated, 18 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 92 have an industry lead sponsor. The 10 most frequent:
Erasmus Medical Center is the lead sponsor of 479 studies on the registry; 182 are open to participants now.
Erasmus Medical Center has 8 studies filed under Glioblastoma — fewer than ten, so there is no comparison to draw.
10 of the studies in Glioblastoma with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05904119Phase 3European Organisation for Research and Treatment of Cancer - EORTCLomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study | 2027-09 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT07121842Erasmus Medical CenterGlioblastoma Imaging for the Detection of Tumor Progression Using APTw-CEST MRI | 2027-01 |
| NCT04868396Maastricht Radiation OncologyPatient-derived Glioma Stem Cell Organoids | 2027-01-01 |
| NCT05641220Erasmus Medical CenterBiopsy Versus Resection in Elderly Glioblastoma Patients. A Prospective Cohort Study. | 2027-01-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 92 studies in Glioblastoma with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is set up as a prospective observational cohort study to identify if either biopsy or resection should be the surgical modality of choice in elderly glioblastoma patients with a newly diagnosed tumor. Patients who are considered eligible for GBM resection or biopsy will be included. Through shared-decision making patients and their treating physicians will decide upon resection or biopsy. Written informed consent will be obtained. Participants will be followed for 1 year postoperative to assess potential differences in health-related quality of life and overall survival.
Follow-up will consist of health-related quality of life questionaires and neurological assessment at 6 weeks, 3 months, 6 months and 12 months postoperative. Additionally Cognitive and neuro-linguistic tests will be done at 3 months postoperative. These will be compared to results pre-operative.
After surgery, patients will receive standard adjuvant treatment with concomitant Temozolomide and radiation therapy, and standard follow-up. Patients in whom the diagnosis GBM is not confirmed in histological analyses will be excluded from the study. Total study duration will be 4 years, of which 3 years will comprise patient inclusion, with a follow-up duration of 1 year.
Adults with presumed Glioblastoma on first diagnostic MRI-scan.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Newly diagnosed elderly (\>70 years of age) glioblastoma patients who undergo biopsy
Newly diagnosed elderly (\>70 years of age) glioblastoma patients who undergo resection
Overall survival (OS)
Defined as the time from diagnosis to the death of the patient from any cause
Time frame: 12 months
The difference in mean change score of physical functioning, as measured with the EORTC QLQ-C30 physical functioning scale, between the two groups at 6 weeks and 3 months after surgery compared to mean score on baseline
Measured with the European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30), a higher scores means a worse outcome. We assume a minimally important difference of 7 between the 2 groups.
Time frame: 6 weeks and 3 months after surgery
Progression-free survival (PFS), defined as the time from diagnosis to disease progression
Increase in residual tumor volume of more than 25%, or occurrence of a new tumor lesion with a volume greater than 0.175cm3), or death. As according to the RANO criteria.
Time frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months after surgery
The difference in mean change score of physical functioning, as measured with the EORTC QLQ-C30 physical functioning scale, between the two groups at 6 months and 12 months after surgery compared to mean score on baseline.
Measured with the European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30), a higher scores means a worse outcome.
Time frame: at 6 months and 12 months after surgery
The proportion of patients with deterioration, improvement or stable physical functioning, as measured with the EORTC QLQ-C30 physical functioning scale at 6 weeks and 3 months compared to baseline.
Measured with the European Organisation for Research and Treatment of Cancer Core Quality of Life questionnaire (EORTC QLQ-C30), a higher scores means a worse outcome.
Time frame: 6 weeks and 3 months after surgery
Descriptive reporting of changes in the mean scores on the other health-related quality of life (HRQoL) scales at 6 weeks and 3 months after surgery.
HRQoL will be measured using the Measured with the European Organisation for Research and Treatment of Cancer (EORTC) Core Quality of Life questionnaire (QLQ-C30), EORTC , EORTC brain cancer module (QLQ-BN20) and EuroQol 5 Dimensions (EQ-5D) questionnaires. A higher scores means a worse outcome.
Time frame: at 6 weeks and 3 months postoperative
Proportion of patients with NIHSS (National Institute of Health Stroke Scale) deterioration, improvement or stability at 6 weeks and 3 months after surgery
In which deterioration is defined as an increase of at least one point and improvement as a decrease of at least one point on the total NIHSS score compared to this score at baseline.
Time frame: at 6 weeks and 3 months postoperative
Descriptive reporting of differences between the groups in cognitive and neuro-linguistic screening at 3 months compared to baseline.
as measured by the Aphasia Bedside Check (ABC), Shortened Token Test, verbal fluency (category and letter), Montreal Cognitive Assessment (MOCA) and optionally CAT-NL Picture Description and Object Naming.
Time frame: 3 months postoperative
Comparison of the (S)AEs in both groups.
Time frame: 6 weeks postoperative
Cost-effectiveness between the two treatments.
Measured as total intramural medical costs, for a 1 year time horizon
Time frame: 12 months postoperative
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Jan 2023; primary completion for Jan 2027, 48 months later.
Of 85 non-industry observational studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 96. This study's planned 48 months is below that.
Counting every sponsor, half of 100 studies reached it within 52 months; a quarter within 33 and three quarters within 96.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.